Full Press Release Details
Charley brings 30 years of experience to operational finance leadership, financial planning and strategy development, and general management of G&A functions after 25 years in life science executive roles and 5 years of strategy consulting. Most recently, Charley was CFO of CERo Therapeutics (Nasdaq:CERO) where he prepared the company for a complex deSPAC transaction and helped launch CERo as a public company. Prior CFO roles include positions at iCAD, Inc. (Nasdaq:ICAD), GI Dynamics, Inc. (ASX:GID), multiple private life science companies, and a variety of consulting CFO projects. Before entering the life sciences industry as Senior Director of Financial Planning and Analysis at Transkaryotic Therapies, Inc. (Nasdaq:TKTX), Charley was a strategy consulting partner at Mercer Management Consulting. Charley earned a bachelor’s degree in Biology from Colgate University and master’s degrees in Molecular Genetics and Business Administration from The University of Chicago.